MMIRF (MedMira) Accounts Payable: $2.33 Mil (As of Jan. 2026)


What is MedMira Accounts Payable?

MedMira MMIRF +302.48% Accounts Payable is $2.33 Mil as of Jan. 2026. The stock has 6 warning signs investors should review.

MedMira's Accounts Payable for the quarter that ended in Jan. 2026 was $2.33 Mil.

MedMira's quarterly Accounts Payable increased from Jul. 2025 ($2.13 Mil) to Oct. 2025 ($2.23 Mil) and increased from Oct. 2025 ($2.23 Mil) to Jan. 2026 ($2.33 Mil).

MedMira's annual Accounts Payable declined from Jul. 2023 ($2.47 Mil) to Jul. 2024 ($1.98 Mil) but then increased from Jul. 2024 ($1.98 Mil) to Jul. 2025 ($2.13 Mil).

MedMira Accounts Payable Historical Data

* Premium members only.

The historical data trend for MedMira's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMira Accounts Payable Chart

MedMira Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.16 2.13 2.47 1.98 2.13

MedMira Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.04 1.92 2.13 2.23 2.33

MedMira Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $2.33 Mil mean?
MedMira (MMIRF) has a Accounts Payable of $2.33 Mil as of Jan. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on MedMira and its competitors.
Is MedMira's Accounts Payable too high?
MedMira's current Accounts Payable is $2.33 Mil.
How does MedMira's Accounts Payable compare to VRTX and REGN?
MedMira's Accounts Payable of $2.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on MedMira and its competitors. MedMira's current Accounts Payable is $2.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMira stock overvalued right now?
MedMira (MMIRF) has a current Accounts Payable of $2.33 Mil. The current Accounts Payable is $2.33 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For MedMira (MMIRF), the current Accounts Payable is $2.33 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedMira Business Description

Other Exchanges MIR:Canada
Address 155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.